Looks like you have JavaScript disabled. For the full Twine experience, you will need to re-enable it.

I'm a pharmacist and drug development scientist with a BS in Pharmacy and Pharmacology from Duke University and about two years of industry experience at Gilead Sciences. My background spans antiviral drug metabolism, clinical pharmacokinetics, and cross-functional collaboration with regulatory affairs and clinical operations teams. I translate complex pharmacological data into clear, actionable insights—whether for an IND submission or a cross-departmental briefing. I enjoy working at the intersection of bench science and strategic drug development, and I’m particularly interested in infectious disease and oncology pipelines.…I'm a pharmacist and drug development scientist with a BS in Pharmacy and Pharmacology from Duke University and about two years of industry experience at Gilead Sciences. My background spans antiviral drug metabolism, clinical pharmacokinetics, and cross-functional collaboration with regulatory affairs and clinical operations teams. I translate complex pharmacological data into clear, actionable insights—whether for an IND submission or a cross-departmental briefing. I enjoy working at the intersection of bench science and strategic drug development, and I’m particularly interested in infectious disease and oncology pipelines.

Elona Clemons

Data Scientist, Developer, Programmer, +4





I'm a pharmacist and drug development scientist with a BS in Pharmacy and Pharmacology from Duke University and about two years of industry experience at Gilead Sciences. My background spans antiviral drug metabolism, clinical pharmacokinetics, and cross-functional collaboration with regulatory affairs and clinical operations teams. I translate complex pharmacological data into clear, actionable insights—whether for an IND submission or a cross-departmental briefing. I enjoy working at the intersection of bench science and strategic drug development, and I’m particularly interested in infectious disease and oncology pipelines.…I'm a pharmacist and drug development scientist with a BS in Pharmacy and Pharmacology from Duke University and about two years of industry experience at Gilead Sciences. My background spans antiviral drug metabolism, clinical pharmacokinetics, and cross-functional collaboration with regulatory affairs and clinical operations teams. I translate complex pharmacological data into clear, actionable insights—whether for an IND submission or a cross-departmental briefing. I enjoy working at the intersection of bench science and strategic drug development, and I’m particularly interested in infectious disease and oncology pipelines.

Available to hire

I’m a pharmacist and drug development scientist with a BS in Pharmacy and Pharmacology from Duke University and about two years of industry experience at Gilead Sciences. My background spans antiviral drug metabolism, clinical pharmacokinetics, and cross-functional collaboration with regulatory affairs and clinical operations teams.

I translate complex pharmacological data into clear, actionable insights—whether for an IND submission or a cross-departmental briefing. I enjoy working at the intersection of bench science and strategic drug development, and I’m particularly interested in infectious disease and oncology pipelines.

Skills

Experience Level

Expert

Expert

Expert

Expert

Expert

Expert

Expert

Intermediate

Intermediate

Language

English

Fluent

Work Experience

Associate Scientist I — Drug Metabolism & Pharmacokinetics (DMPK) at Gilead Sciences, Inc.

January 1, 2024 - Present

Conduct in vitro ADME studies for pipeline compounds, including microsomal stability assays, CYP reaction phenotyping, and plasma protein binding; results informed go/no-go decisions on three Phase I candidates in 2024. Developed and partially validated an LC-MS/MS bioanalytical method for quantifying a novel nucleotide prodrug in human plasma, reducing sample analysis turnaround time by roughly 20%. Collaborate with the clinical pharmacology team to model population PK parameters using Phoenix WinNonlin; contributed data packages supporting two IND amendments submitted to FDA. Participated in a cross-functional working group evaluating DDI risk for a late-stage HIV integrase inhibitor, compiling mechanistic static model analyses that aligned with the regulatory team's labeling strategy. Mentored two summer interns (2024 cohort). Maintain laboratory compliance with internal SOPs and ICH guidelines; completed GLP refresher training and annual biosafety certification without exceptions.

Pharmacy Intern — Clinical Operations at Duke University Health System

May 1, 2022 - December 1, 2023

Rotated through four clinical pharmacy settings — inpatient oncology, transplant medicine, ambulatory HIV clinic, and central pharmacy operations — accumulating over 1,600 supervised practice hours. Assisted attending pharmacists in medication reconciliation reviews for newly admitted patients in the bone marrow transplant unit; identified three clinically significant drug-drug interactions during a single month rotation. Supported the ambulatory HIV clinic pharmacist in managing ART regimen optimization for approximately 40 patients, including adherence counseling and insurance prior authorization follow-up. Contributed to a departmental quality improvement project examining 30-day readmission rates related to anticoagulation therapy; helped compile and analyze retrospective chart data for a sample of 85 patients, findings later presented at an internal pharmacy grand rounds. Processed and verified a high volume of outpatient prescriptions under pharmacist supervision, maintaining

Undergraduate Research Assistant — Pharmacology Laboratory at Duke University, Department of Pharmacology & Cancer Biology

September 1, 2020 - April 1, 2022

Worked in the laboratory studying small-molecule modulators of nuclear receptor signaling. Independently executed cell viability assays (MTT and CellTiter-Glo) across a panel of cancer cell lines to assess cytotoxicity profiles of novel synthetic compounds, generating dose-response data for approximately 30 unique structures over two academic years. Assisted a postdoctoral fellow in preparing figures and methodology sections for a manuscript submitted to the Journal of Medicinal Chemistry (2022). Maintained detailed laboratory notebooks compliant with the department's data integrity policy; notebooks audited without citation during a routine compliance review. Presented a poster summarizing first-year research findings at the Duke Undergraduate Research Symposium (Spring 2021). Trained two first-year undergraduates on standard laboratory safety protocols, pipetting technique, and cell culture maintenance during the 2021–2022 academic year.